IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

Amary, M Fernanda, Bacsi, Krisztian, Maggiani, Francesca, Damato, Stephen, Halai, Dina, Berisha, Fitim, Pollock, Robin, O'Donnell, Paul +8 more·2011·The Journal of Pathology

DOI 10.1002/path.2913

Cited by (1,000)

Items 401–500 of 1,000

IDH1 and IDH2 Mutations in Colorectal Cancers
Jialing Huang, Li‐Hui Tseng, Vamsi Parini, Parvez M. Lokhandwala, Aparna Pallavajjala, Erika F. Rodriguez, Rena R. Xian, Liam Chen, Christopher D. Gocke, James R. Eshleman et al. · 2021 · American Journal of Clinical Pathology
Isocitrate dehydrogenase gene variants in cancer and their clinical significance
Thomas A.D. Cadoux-Hudson, Christopher John Schofield, James McCullagh · 2021 · Biochemical Society Transactions
Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas
Hao‐Wen Sim, Romina Nejad, Wenjiang Zhang, Farshad Nassiri, Warren P. Mason, Kenneth Aldape, Gelareh Mohammed Zadeh, Eric Xueyu Chen · 2019 · Clinical Cancer Research
Alpha Ketoglutarate Exerts In Vitro Anti-Osteosarcoma Effects through Inhibition of Cell Proliferation, Induction of Apoptosis via the JNK and Caspase 9-Dependent Mechanism, and Suppression of TGF-β and VEGF Production and Metastatic Potential of Cells
Katarzyna Kaławaj, Adrianna Sławińska-Brych, Magdalena Mizerska-Kowalska, Aleksandra Żurek, Agnieszka A. Bojarska-Junak, Martyna Kandefer‐Szerszeń, Barbara Zdzisińska · 2020 · International Journal of Molecular Sciences
Fresh Tissue Multi-omics Profiling Reveals Immune Classification and Suggests Immunotherapy Candidates for Conventional Chondrosarcoma
Binghao Li, Guoqi Li, Xiaobo Yan, Dan Zhu, Patrick P. Lin, Zenan Wang, Hao Qu, Xuexin He, Yanbiao Fu, Xiuliang Zhu et al. · 2021 · Clinical Cancer Research
Biomarkers Classification and Therapeutic Decision-Making for Malignant Gliomas
Adriana Olar, Kenneth Aldape · 2012 · Current Treatment Options in Oncology
Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d ‐2‐hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma
Nissreen Mohammad, Derek Wong, Amy M. Lum, Jonah Lin, Julie Ho, Cheng‐Han Lee, Stephen S. F. Yip · 2019 · Histopathology
A system-level approach identifies HIF-2α as a critical regulator of chondrosarcoma progression
Hyeonkyeong Kim, Yongsik Cho, Hyeon Seop Kim, Donghyun Kang, Donghyeon Cheon, Yi‐Jun Kim, Moon Jong Chang, Kyoung Min Lee, Chong Bum Chang, Seung‐Baik Kang et al. · 2020 · Nature Communications
Challenges of Systemic Therapy Investigations for Bone Sarcomas
Kenji Nakano · 2022 · International Journal of Molecular Sciences
Recurrent IDH2 Mutations in Salivary Gland Striated Duct Adenoma Define an Expanded Histologic Spectrum Distinct From Canalicular Adenoma
Lisa M. Rooper, Abbas Agaimy, Adel M. Assaad, Munita Meenu Bal, Henrietta C. Eugene, Jeffrey Gagan, Hiro Nonogaki, Doreen N. Palsgrove, Akeesha A. Shah, Edward B. Stelow et al. · 2022 · The American Journal of Surgical Pathology
Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas
Huimin Hu, Zheng Wang, Yanwei Liu, Chuanbao Zhang, Mingyang Li, Wenlong Zhang, Kuanyu Wang, Jinquan Cai, Wen Cheng, Hua Huang et al. · 2014 · Cancer Letters
Chondroblastic osteosarcoma: Cytomorphologic characteristics and differential diagnosis on FNA
Christopher J. VandenBussche, Srividya Sathiyamoorthy, Paul E. Wakely, Syed Zulfiqar Ali · 2016 · Cancer Cytopathology
Expression of PD-L1/PD-L2 is associated with high proliferation index of Ki-67 but not with TP53 overexpression in chondrosarcoma
Xiao Feng Yang, Guoxing Zhu, Zhengjie Yang, Ke Zeng, Fengxiang Liu, Junying Sun · 2018 · The International Journal of Biological Markers
The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma
Snjezana Doğan, Denise Frosina, Miriam Fayad, Thais Basili, Bárbara Alemar, Marc K. Rosenblum, Laura H. Tang, Meera Hameed, Bin Xu, Ronald A. Ghossein et al. · 2018 · Modern Pathology
IDH Mutations in Chondrosarcoma: Case Closed or Not?
Sanne Venneker, Judith V.M.G. Bovée · 2023 · Cancers
Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity
Mengyuan Cai, Jianyi Zhao, Qiang Ding, Jifu Wei · 2024 · Heliyon
The oncometabolite d‑2‑hydroxyglutarate induces angiogenic activity through the vascular endothelial growth factor receptor 2 signaling pathway
Jiyoon Seok, Soohyun Yoon, Sun‐Hee Lee, Jong Hwa Jung, You Mie Lee · 2018 · International Journal of Oncology
New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions
Concetta Schiano, Andrea Soricelli, Filomena de Nigris, Claudio Napoli A · 2018 · Expert Review of Clinical Immunology
Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth
Luyuan Li, Xiaoyu Hu, Josiane E. Eid, Andrew Eric Rosenberg, Breelyn Ann Wilky, Yuguang J. Ban, Xiaodian Sun, Karina A. Galoian, Joanna DeSalvo, Jinbo Yue et al. · 2020 · Cancers
Dedifferentiated and undifferentiated neoplasms: A conceptual approach
Ezra G. Baraban, Kumarasen Cooper · 2020 · Seminars in Diagnostic Pathology
Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations
Pasquale Persico, Elena Lorenzi, Agnese Losurdo, Angelo Dipasquale, Antonio Di Muzio, Pierina Navarria, Federico Pessina, Letterio Salvatore Politi, Giuseppe Lombardi, Armando Santoro et al. · 2022 · Cancers
IDH Mutation Detection in Formalin‐Fixed Paraffin‐Embedded Gliomas Using Multiplex PCR and Single‐Base Extension
Marco Perizzolo, Bob Winkfein, Susan Hui, Wally Krulicki, Jennifer Ai-wen Chan, Douglas J. Demetrick · 2012 · Brain Pathology
Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults
Adriana Olar, Aditya Raghunathan, Constance T. Albarracin, Kenneth Aldape, Daniel P. Cahill, Suzanne Zein-Eldin Powell, Jerry Clay Goodman, Gregory N. Fuller · 2011 · Annals of Diagnostic Pathology
IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution
Erika F. Rodriguez, Federico De Marchi, Parvez M. Lokhandwala, Deborah Belchis, Rena R. Xian, Christopher D. Gocke, James R. Eshleman, Peter Bela Illei, M. Li · 2020 · Cancer Medicine
Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes
Sinthu Pathmanapan, Olga Ilkayeva, John Thomas Martin, Adrian Kwan Ho Loe, Hongyuan Zhang, Guofang Zhang, Christopher B. Newgard, Jay Steven Wunder, Benjamin Aaron Alman · 2021 · Cancer & Metabolism
Mitochondrial signaling pathways and their role in cancer drug resistance
Ashwani Sharma, Tarun Virmani, Girish Kumar, Anjali Sharma, Reshu Virmani, Dalapathi B Gugulothu, Kuldeep Singh, Shashi Kiran Misra, Kamla Pathak, Nitin Chitranshi et al. · 2024 · Cellular Signalling
Update on the imaging features of the enchondromatosis syndromes
Ban Sharif, Daniel Lindsay, Asif Saifuddin · 2021 · Skeletal Radiology
Systemic Therapy for Chondrosarcoma
Adam Rock, Sana Ali, Warren Allen Chow · 2022 · Current Treatment Options in Oncology
Clear cell chondrosarcoma: Cytologic findings in six cases
Xiaoyin “Sara” Jiang, Liron Pantanowitz, Marilyn M. Bui, Robert J. Esther, Debra A. Budwit, Leslie G. Dodd · 2013 · Diagnostic Cytopathology
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis
Yaxia Zhang, Ana Cristina Paz-Mejia, Harry Thomas Temple, Jonathan C. Trent, Andrew Eric Rosenberg · 2014 · Human Pathology
Glucose metabolism and its direct action in cancer and immune regulation: opportunities and challenges for metabolic targeting
Bo‐Syong Pan, Che-Chia Hsu, Hsin‐En Wu, Yuan-Ru Chen, Xiaobo Zhou, Shu‐Chi Wang, Chia‐Yang Li, Hui-Kuan Lin · 2025 · Journal of Biomedical Science
Isocitrate dehydrogenase 1: what it means to the neurosurgeon
Tiffany R. Hodges, Bryan D. Choi, Darell D. Bigner, Hai Yan, John Howard Sampson · 2013 · Journal of neurosurgery
Round Cell Tumors of Bone
Shi Wei, Gene P. Siegal · 2014 · Advances in Anatomic Pathology
Isocitrate dehydrogenase mutations in chondrosarcoma
Georges Azzi, Michel Velez, Maria Cecília Mathias-Machado · 2014 · Current Opinion in Oncology
Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults
Angela Shien Ling Pang, Mariana Carbini, Robert G. Maki · 2016 · JAMA Oncology
Targeted next-generation sequencing of dedifferentiated chondrosarcoma in the skull base reveals combined TP53 and PTEN mutations with increased proliferation index, an implication for pathogenesis
Lu Gao, Xiafei Hong, Xiaopeng Guo, Dengfeng Cao, Xiaohuan Gao, Thomas F. DeLaney, Xinqi Gong, Rongrong Chen, Jianjiao Ni, Yong Yao et al. · 2016 · Oncotarget
Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition
Victor Ruiz‐Rodado, Adrian Lita, Tyrone Dowdy, Orieta Celiku, Alejandra Cavazos Saldana, Herui Wang, Chunzhang Yang, Raj Chari, Aiguo Li, Wei Zhang et al. · 2020 · Cancer & Metabolism
Targeting Cancer Metabolism and Current Anti-Cancer Drugs
Witchuda Sukjoi, Jarunya Ngamkham, Paul V. Attwood, Sarawut Jitrapakdee · 2021 · Advances in experimental medicine and biology
The impact of mitochondria on cancer treatment resistance
Michelle van der Merwe, Gustav van Niekerk, Carla Fourie, Manisha du Plessis, Anna‐Mart Engelbrecht · 2021 · Cellular Oncology
Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma
Josephine Kam Tai K. Dermawan, Khedoujia Nafa, Abhinita S. Mohanty, Yingjuan Xu, Ivelise Rijo, Jacklyn Casanova, Liliana B. Villafania, Jamal K. Benhamida, Ciara Marie Kelly, William D. Tap et al. · 2023 · Cancer Research Communications
The role of mutation of metabolism-related genes in genomic hypermethylation
Joshua J. Waterfall, J. Keith Killian, Paul S. Meltzer · 2014 · Biochemical and Biophysical Research Communications
Genetic aberrations and molecular biology of skull base chordoma and chondrosarcoma
Yohei Kitamura, Hikaru Sasaki, Kazunari Yoshida · 2017 · Brain Tumor Pathology
Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype
Agnieszka E. Zając, Sylwia Katarzyna Król, Piotr Lukasz Rutkowski, Anna Malgorzata Czarnecka · 2021 · Cancers
New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy
Fabio Andreozzi, Fulvio Massaro, Sébastian Wittnebel, Chloé Spilleboudt, Philippe Lewalle, Adriano Salaroli · 2022 · International Journal of Molecular Sciences
Chemotherapy for Bone Sarcomas in Adults: The MD Anderson Experience
Robert S. Benjamin, Michael J. Wagner, John Andrew Livingston, Vinod Ravi, SHREYASKUMAR R. PATEL · 2015 · American Society of Clinical Oncology Educational Book
Asperspiropene A, a novel fungal metabolite as an inhibitor of cancer-associated mutant isocitrate dehydrogenase 1
Yan He, Mengzhu Zheng, Qin Li, Zhengxi Hu, Hucheng Zhu, Junjun Liu, Jianping Wang, Yongbo Xue, Hua Li, Yonghui Zhang · 2017 · Organic Chemistry Frontiers
The clinical significance of isocitrate dehydrogenase 2 in esophageal squamous cell carcinoma.
Xuan Chen, Wenzhe Xu, Cong Wang, Fang Liu, Shanghui Guan, Yi Sun, Xintong Wang, Dianzheng An, Zhihua Wen, Pengxiang Chen et al. · 2017 · PubMed Central
The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids
Junqiang Wei, Xinyue Liu, Ting Li, Peipei Xing, Chao Zhang, Jilong Yang · 2020 · Journal of Cancer
Post-translational regulation contributes to the loss of LKB1 expression through SIRT1 deacetylase in osteosarcomas
Nadège Presneau, Laure Alice Duhamel, Hongtao Ye, Roberto Tirabosco, Adrienne Margaret Flanagan, Malihe Eskandarpour · 2017 · British Journal of Cancer
A double surrogate approach for the quantitation of 2-Hydroxyglutarate – An oncometabolite in human brain tumors via LC-MS/MS
Feng Qin Yin, Jennifer Keller, Dennis H. Kraus, Heidi Mangus, Fumin Li, Guowen Liu · 2019 · Journal of Pharmaceutical and Biomedical Analysis
Prognostic impact of IDH mutations in chondrosarcoma
Makoto Nakagawa, Masaya Sekimizu, Makoto Endo, Eisuke Kobayashi, Shintaro Iwata, Suguru Fukushima, Akihiko Yoshida, Issay Kitabayashi, Hitoshi Ichikawa, Akira Kawai et al. · 2021 · Journal of Orthopaedic Science
The Small Round Cell Sarcomas Complexities and Desmoplastic Presentation
Henryk A. Domanski · 2022 · Acta Cytologica
Insight into the interplay between mitochondria-regulated cell death and energetic metabolism in osteosarcoma
Hong-Toan Lai, Nataliia Naumova, Antonin Marchais, Nathalie Gaspar, Birgit Geoerger, Catherine Brenner · 2022 · Frontiers in Cell and Developmental Biology
Molecular In-Depth Characterization of Chondrosarcoma for Current and Future Targeted Therapies
Sebastian Gottfried Walter, Peter Knöll, Peer Eysel, Alexander Quaas, Christopher Gaisendrees, Robert Nißler, Lena Hieggelke · 2023 · Cancers
Genetic characterization of skull base chondrosarcomas
Hiroki Kanamori, Yohei Kitamura, Tokuhiro Kimura, Kazunari Yoshida, Hikaru Sasaki · 2015 · Journal of neurosurgery
Genetic profiling of a chondroblastoma‐like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1‐FGFR1 gene fusion
Karim H. Saba, Louise Cornmark, Marianne Rissler, Thoas Fioretos, Kristina Åström, Felix Haglund, Andrew Eric Rosenberg, Otte Brosjö, Karolin H. Nord · 2019 · Genes Chromosomes and Cancer
Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma
Sanne Venneker, Károly Szuhai, Pancras C.W. Hogendoorn, Judith V.M.G. Bovée · 2019 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
Cancer-Associated Isocitrate Dehydrogenase Mutations
Katharine E. Yen, David P. Schenkein · 2012 · The Oncologist
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
William D. Tap, Gregory Michael Cote, Howard A. Burris, Lia Gore, ANTHONY D. ELIAS, Murali Beeram, Anthony Paul Conley, Diego A. Gianolio, Zhe Qu, Susan S. Pandya et al. · 2025 · Clinical Cancer Research
Isocitrate dehydrogenase 1 and 2 mutations in gliomas
Magdalena Megova Houdova, Jir̆ı́ Drábek, Vladimíra Koudeláková, Radek Trojanec, Ondřej Kalita, Marián Hajdúch · 2014 · Journal of Neuroscience Research
Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors
Qiangang Zheng, Shuai Tang, Xianlei Fu, Ziqi Chen, Yan Ye, Xiaojing Lan, Lei Jiang, Ying Huang, Jian Ding, Meiyu Geng et al. · 2017 · Bioorganic & Medicinal Chemistry Letters
Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway
Ruben D. Addie, Yvonne de Jong, Gaia Alberti, Alwine B. Kruisselbrink, Ivo Que, Hans J. Baelde, Judith V.M.G. Bovée · 2019 · Journal of bone oncology
Distinctive Head and Neck Bone and Soft Tissue Neoplasms
Bibianna Purgina, Chi K. Lai · 2017 · Surgical pathology clinics
The role of TET-mediated DNA hydroxymethylation in prostate cancer
Elien Smeets, Andy G. Lynch, Stefan Preković, Thomas Van den Broeck, Lisa Moris, Christine Helsen, Steven Joniau, Frank Claessens, Charlie E. Massie · 2017 · Molecular and Cellular Endocrinology
Insights from Large-Scale Cancer Genome Sequencing
Elaine R. Mardis · 2018 · Annual Review of Cancer Biology
New Approaches with Precision Medicine in Adult Brain Tumors
Annette Leibetseder, Matthias Preusser, Anna Sophie Berghoff · 2022 · Cancers
Glandular differentiation in dedifferentiated chondrosarcoma: molecular evidence of a rare phenomenon
George Jour, Yajuan Liu, Robert W. Ricciotti, Colin C. Pritchard, Benjamin L. Hoch · 2015 · Human Pathology
The molecular pathogenesis of dedifferentiated chondrosarcoma
Akio Sakamoto · 2014 · Indian Journal of Orthopaedics
A diagnostic approach to bone tumours
Adrienne Margaret Flanagan, Daniel Lindsay · 2017 · Pathology
Magnetic resonance imaging follow-up of chondroid tumors: regression vs. progression
Bo Mi Chung, Sung Hwan Hong, Hye Jin Yoo, Ja-Young Choi, Hee-Dong Chae, Dong Hyun Kim · 2017 · Skeletal Radiology
The hypoxic microenvironment: A determinant of cancer stem cell evolution
Amancio Carnero, Matilde Esther LLeonart · 2015 · Inside the Cell
D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant–Induced MIR148A Promoter Methylation
Tie Li, Christopher D. Cox, Byram Hirsch Ozer, Nhung T. Nguyen, HuyTram N. Nguyen, Thomas J. Lai, Sichen Li, Fei Liu, Harley I. Kornblum, Linda M. Liau et al. · 2018 · Molecular Cancer Research
Distinct Roles of Glutamine Metabolism in Benign and Malignant Cartilage Tumors With IDH Mutations
Hongyuan Zhang, Vijitha Puviindran, Puviindran Nadesan, Xiruo Ding, Leyao Shen, Yuning J. Tang, Hidetoshi Tsushima, Yasuhito Yahara, Ga I Ban, Guofang Zhang et al. · 2020 · Journal of Bone and Mineral Research
Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation
Sinthu Pathmanapan, Raymond W.M. Poon, Tomasa Barrientos De Renshaw, Puviindran Nadesan, Makoto Nakagawa, Gireesh Seesankar, Adrian Kwan Ho Loe, Hongyuan H. Zhang, Joan Josep Guinovart, Jordi Durán et al. · 2023 · Cell Reports
The Interplay between Dysregulated Metabolism and Epigenetics in Cancer
Mahmoud Adel Bassal · 2023 · Biomolecules
Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents
Eytan M. Stein, Katharine E. Yen · 2017 · Annual Review of Cancer Biology
Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis
Suk Wai Lam, Kirsten van Langevelde, Albert J.H. Suurmeijer, Arjen H.G. Cleven, Judith V.M.G. Bovée · 2019 · Histopathology
Chondrosarcoma: New Molecular Insights, Challenges in Near-Patient Preclinical Modeling, and Therapeutic Approaches
Lorena Landuzzi, Francesca Ruzzi, Pier‐Luigi Lollini, Katia Scotlandi · 2025 · International Journal of Molecular Sciences
Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma
Yen‐Ying Chen, Hsiang‐Ling Ho, Shih‐Chieh Lin, Chih‐Yi Hsu, Donald Ming‐Tak Ho · 2018 · Neurosurgery
Tall cell carcinoma with reverse polarity of breast: report of a case with unique morphologic and molecular features
Mohamed Jassim, C S Premalata, Geeta V. Patil Okaly, Srinivas Chunduri · 2020 · Turkish Journal of Pathology
Sarcoma Metabolomics: Current Horizons and Future Perspectives
Miguel Esperança‐Martins, Isabel Fernandes, Joaquim Soares do Brito, Daniela Macedo, Hugo Vasques, Teresa L. Serafim, Luís Costa, Sérgio Dias · 2021 · Cells
Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma
Makoto Nakagawa, Masayuki Yamaguchi, Makoto Endo, Yukino Machida, Ayuna Hattori, Fumie Tanzawa, Shinji Tsutsumi, Issay Kitabayashi, Akira Kawai, Fumihiko Nakatani · 2022 · Journal of bone oncology
Targeting IDH1/IDH2 mutations in gliomas
Macarena I. de la Fuente · 2022 · Current Opinion in Neurology
Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor
Chujiao Hu, Yu Zuo, Jingqiu Liu, Heng Xu, Weike Liao, Yongjun Dang, Cheng Luo, Lei Tang, Hao Zhang · 2019 · Bioorganic & Medicinal Chemistry Letters
Amphiregulin promotes cisplatin chemoresistance by upregulating ABCB1 expression in human chondrosarcoma
Yu-Wen Huang, Chih‐Yang Lin, Hsiao‐Chi Tsai, Yi‐Chin Fong, Chien-Kuo Han, Yuan‐Li Huang, Wen-Tung Wu, Shih‐Ping Cheng, Hao-Chiun Chang, Kuang‐Wen Liao et al. · 2020 · Aging
The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation
Lizhen Liu, Kaimin Hu, Jingjing Feng, Huafang Wang, Shan Fu, Binsheng Wang, Limengmeng Wang, Yulin Xu, Xiaohong Yu, He Huang · 2021 · BMC Cancer
Multifocal intracranial astrocytoma in a pediatric patient with Ollier disease
Girish Bathla, Sarika Gupta, Cheng Kang Ong · 2012 · Indian journal of radiology and imaging - new series/Indian journal of radiology and imaging/Indian Journal of Radiology & Imaging
Functional roles of CSPG 4/ NG 2 in chondrosarcoma
Nuor Sabah Mohammed Jamil, Asim Azfer, Harrison Worrell, Donald McGovern Salter · 2016 · International Journal of Experimental Pathology
Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with <i>IDH1/2</i> and <i>GNAS</i> mutations
Lyskjær, Iben, Davies, Christopher, Strobl, Anna‐Christina, Hindley, Joanna, James, Steven, Lalam, Radhesh K., Cross, William, Hide, Geoff, Rankin, Kenneth S., Jeys, Lee et al. · 2021 · Molecular Oncology
SOX9 and SATB2 immunohistochemistry cannot reliably distinguish between osteosarcoma and chondrosarcoma on biopsy material
Aarti E. Sharma, Peter Pytel, Nicole A. Cipriani · 2022 · Human Pathology
IDH2-Mutated Sinonasal Tumors: A Review
Bayan Alzumaili, Peter M. Sadow · 2022 · Advances in Anatomic Pathology
Epigenetic Abnormalities in Chondrosarcoma
Michał Bereza, Mateusz Dembiński, Agnieszka E. Zając, Jakub Piątkowski, Monika Dudzisz‐Śledź, Piotr Lukasz Rutkowski, Anna Malgorzata Czarnecka · 2023 · International Journal of Molecular Sciences
Dedifferentiated Chondrosarcoma from Molecular Pathology to Current Treatment and Clinical Trials
Weronika Zając, Julia Dróżdż, Weronika Kisielewska, Weronika Karwowska, Monika Dudzisz‐Śledź, Agnieszka E. Zając, Aneta Maria Borkowska, Anna Szumera‐Ciećkiewicz, Bartłomiej Szostakowski, Piotr Lukasz Rutkowski et al. · 2023 · Cancers
Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
Giulia Trovarelli, Marta Sbaraglia, Andrea Angelini, Elena Bellan, Elisa Pala, Elisa Belluzzi, Assunta Pozzuoli, Chiara Borga, Angelo Paolo Dei Tos, Pietro Ruggieri · 2024 · Clinical Orthopaedics and Related Research
A Systematic Review of Adjuvant Chemotherapy in Localized Dedifferentiated Chondrosarcoma
Shinji Tsukamoto, Andreas F. Mavrogenis, Yuji Nitta, Alberto Righi, Tomoya Masunaga, Kanya Honoki, Hiromasa Fujii, Akira Kido, Yuu Tanaka, Yasuhito Tanaka et al. · 2024 · Current Oncology
High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocytomas
Jason T. Huse, Khédoudja Nafa, Neerav Narendra Shukla, Edward R. Kastenhuber, Ehud Lavi, Cyrus V. Hedvat, Marc Ladanyi, Marc K. Rosenblum · 2011 · Acta Neuropathologica
Dedifferentiated chondrosarcoma with “adamantinoma-like” features: A case report and review of literature
Marco Gambarotti, Alberto Righi, Tommaso Frisoni, Davide María Donati, D. Vanel, Marta Sbaraglia, Angelo Paolo Dei Tos · 2017 · Pathology - Research and Practice
IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma
Xing Y. Zhang, Runchen Miao, Tian Liu, Xiaohong Xiang, Jingxian Gu, Yifan Jia, Zeyu Li, Yunong Fu, Yang He, Yuhua Zhang et al. · 2019 · Biomedicine & Pharmacotherapy
Intracellular cholesterol biosynthesis in enchondroma and chondrosarcoma
Hongyuan Zhang, Qingxia Wei, Hidetoshi Tsushima, Vijitha Puviindran, Yuning J. Tang, Sinthu Pathmanapan, Raymond W.M. Poon, Eyal Ramu, Mushriq Al‐Jazrawe, Jay Steven Wunder et al. · 2019 · JCI Insight
In vitro and in vivo analysis of metabolites involved in the TCA cycle and glutamine metabolism associated with cisplatin resistance in human lung cancer
Jiwei Guo, Jing Yu, Feng Peng, Jinzi Li, Zhi‐Rong Tan, Yao Chen, Tai Rao, Yicheng Wang, Jingbo Peng, Hong‐Hao Zhou · 2021 · Expert Review of Proteomics